跳转至内容
Merck
CN

主要文件

查看所有文档

R3501

利福平

≥95% (HPLC), powder or crystals

别名:

3-(4-甲基-1-哌嗪基亚胺甲基)利福霉素SV, 利米定, 甲哌利福霉素

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C43H58N4O12
化学文摘社编号:
13292-46-1
分子量:
822.94
UNSPSC Code:
51283601
NACRES:
NA.76
PubChem Substance ID:
57654590
EC Number:
236-312-0
Beilstein/REAXYS Number:
5723476
MDL number:
MFCD00151389
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Quality Level

200

assay

≥95% (HPLC)

form

powder or crystals

color

Reddish-brown

pI 

4.84

pKa 

1.7 (4-hydroxyl group), 7.9 (4-piperazine nitrogen)

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria, mycobacteria, viruses

mode of action

protein synthesis | interferes

storage temp.

−20°C

SMILES string

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O

InChI

1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

InChI key

JQXXHWHPUNPDRT-WLSIYKJHSA-N

General description

化学结构:大环内酯物

Application

利福平用于治疗结核病和与结核病相关的分枝杆菌感染。 其广泛应用于自身免疫性胆汁淤积性肝病，原发性胆汁性肝硬化(PBC)的止痒剂。 它已被证明会引起肝炎。

Biochem/physiol Actions

作用方式：通过与RNA聚合酶的β-亚基结合抑制RNA合成的起始。
利福平抑制DNA和蛋白质组装成成熟的病毒颗粒。 它通过与RNA聚合酶的亚基结合抑制RNA合成的起始，从而导致细胞死亡。
抑制DNA和蛋白质组装成成熟的病毒颗粒。

Other Notes

保持容器密闭在干燥通风处。产品对光和湿度敏感。储存在惰性气体中。干燥处保存

Still not finding the right product?

Explore all of our products under 利福平

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
WXBD4775V
WXBD0542V
WXBC9631V
049M4833V
019M4861V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

M I Prince et al.
Gut, 50(3), 436-439 (2002-02-13)
There is evidence to suggest that rifampicin is an effective second line therapy for controlling pruritus in patients with chronic cholestatic liver disease. It is most widely used as an antipruritic agent in the autoimmune cholestatic liver disease, primary biliary
Sandra V Kik et al.
The Journal of infectious diseases, 211 Suppl 2, S58-S66 (2015-03-15)
The potential available market (PAM) for new diagnostics for tuberculosis that meet the specifications of the high-priority target product profiles (TPPs) is currently unknown. We estimated the PAM in 2020 in 4 high-burden countries (South Africa, Brazil, China, and India)
Samy Figueiredo et al.
Antimicrobial agents and chemotherapy, 53(6), 2657-2659 (2009-03-25)
Two clonally related Acinetobacter baumannii isolates, A1 and A2, were obtained from the same patient. Isolate A2, selected after an imipenem-containing treatment, showed reduced susceptibility to carbapenems. This resistance pattern was related to insertion of the ISAba1 element upstream of
查看所有相关文献

全球贸易项目编号

货号GTIN
R3501-25G04061835548262
R3501-5G04061835522484
R3501-1G04061835548255
R3501-250MG04061835513970